EP2772486A4 - Inhibiteur de kinase et méthode de traitement de maladies associées - Google Patents
Inhibiteur de kinase et méthode de traitement de maladies associéesInfo
- Publication number
- EP2772486A4 EP2772486A4 EP12843502.1A EP12843502A EP2772486A4 EP 2772486 A4 EP2772486 A4 EP 2772486A4 EP 12843502 A EP12843502 A EP 12843502A EP 2772486 A4 EP2772486 A4 EP 2772486A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- treatment
- kinase inhibitor
- related diseases
- diseases
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110327240.9A CN103073508B (zh) | 2011-10-25 | 2011-10-25 | 激酶抑制剂及治疗相关疾病的方法 |
PCT/CN2012/001432 WO2013060098A1 (fr) | 2011-10-25 | 2012-10-25 | Inhibiteur de kinase et méthode de traitement de maladies associées |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2772486A1 EP2772486A1 (fr) | 2014-09-03 |
EP2772486A4 true EP2772486A4 (fr) | 2015-03-11 |
EP2772486B1 EP2772486B1 (fr) | 2016-03-16 |
Family
ID=48150228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12843502.1A Active EP2772486B1 (fr) | 2011-10-25 | 2012-10-25 | Inhibiteur de kinase et méthode de traitement de maladies associées |
Country Status (11)
Country | Link |
---|---|
US (1) | US9150522B2 (fr) |
EP (1) | EP2772486B1 (fr) |
JP (1) | JP5909558B2 (fr) |
KR (1) | KR101942439B1 (fr) |
CN (1) | CN103073508B (fr) |
AU (1) | AU2012327780B2 (fr) |
CA (1) | CA2853440C (fr) |
ES (1) | ES2578605T3 (fr) |
HK (1) | HK1201524A1 (fr) |
PT (1) | PT2772486T (fr) |
WO (1) | WO2013060098A1 (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103073508B (zh) | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
US9782406B2 (en) | 2011-10-25 | 2017-10-10 | Peking University Shenzhen Graduate School | Kinase inhibitor and method for treatment of related diseases |
JP6575950B2 (ja) | 2012-07-24 | 2019-09-18 | ファーマサイクリックス エルエルシー | Bruton型チロシンキナーゼ(Btk)阻害剤に対する耐性を伴う変異 |
CN104109127B (zh) * | 2013-04-19 | 2019-11-05 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
TR201911140T4 (tr) | 2013-10-21 | 2019-08-21 | Merck Patent Gmbh | Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları. |
CN105399685B (zh) * | 2014-09-16 | 2018-05-22 | 深圳微芯生物科技有限责任公司 | 作为选择性jak3和/或jak1激酶抑制剂的芳杂环化合物的制备方法及其应用 |
CN105399686B (zh) * | 2014-09-16 | 2018-05-22 | 深圳微芯生物科技有限责任公司 | 嘧啶衍生物、其制备方法及其应用 |
WO2017063103A1 (fr) * | 2015-10-12 | 2017-04-20 | Peking University Shenzhen Graduate School | Nouveaux inhibiteurs et nouvelles sondes pour kinases et leurs utilisations |
CN107021963A (zh) | 2016-01-29 | 2017-08-08 | 北京诺诚健华医药科技有限公司 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
JP2020511462A (ja) | 2016-12-03 | 2020-04-16 | ジュノー セラピューティクス インコーポレイテッド | キナーゼ阻害剤との組み合わせで治療用t細胞を使用するための方法および組成物 |
CN109305944B (zh) * | 2017-07-28 | 2022-09-02 | 深圳睿熙生物科技有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CN109422696B (zh) * | 2017-09-04 | 2020-10-30 | 北京睿熙生物科技有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CN111170986A (zh) | 2018-11-13 | 2020-05-19 | 北京睿熙生物科技有限公司 | 布鲁顿酪氨酸激酶的抑制剂 |
CN113234026B (zh) * | 2021-03-28 | 2024-04-30 | 北京大学深圳研究生院 | 具有b淋巴细胞酪氨酸激酶抑制活性的化合物及其应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
US6414013B1 (en) | 2000-06-19 | 2002-07-02 | Pharmacia & Upjohn S.P.A. | Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention |
AU2006227628A1 (en) * | 2005-03-16 | 2006-09-28 | Targegen, Inc. | Pyrimidine compounds and methods of use |
PL1891066T3 (pl) * | 2005-05-13 | 2011-05-31 | Irm Llc | Związki i kompozycje jako inhibitory kinazy białkowej |
US7754717B2 (en) * | 2005-08-15 | 2010-07-13 | Amgen Inc. | Bis-aryl amide compounds and methods of use |
BRPI0618135A2 (pt) * | 2005-11-03 | 2011-08-16 | Irm Llc | compostos e composições como inibidores da proteìna quinase |
WO2008008234A1 (fr) * | 2006-07-07 | 2008-01-17 | Targegen, Inc. | Inhibiteurs de type 2-amino-5-substituant-pyrimidines |
AR063946A1 (es) * | 2006-09-11 | 2009-03-04 | Cgi Pharmaceuticals Inc | Determinadas pirimidinas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
CN102083800A (zh) * | 2008-06-27 | 2011-06-01 | 阿维拉制药公司 | 杂芳基化合物和其用途 |
WO2010144647A1 (fr) * | 2009-06-12 | 2010-12-16 | Bristol-Myers Squibb Company | Composés de nicotinamide utiles en tant que modulateurs de kinases |
CN103073508B (zh) | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
-
2011
- 2011-10-25 CN CN201110327240.9A patent/CN103073508B/zh active Active
-
2012
- 2012-10-25 JP JP2014537452A patent/JP5909558B2/ja not_active Expired - Fee Related
- 2012-10-25 AU AU2012327780A patent/AU2012327780B2/en not_active Ceased
- 2012-10-25 CA CA2853440A patent/CA2853440C/fr not_active Expired - Fee Related
- 2012-10-25 ES ES12843502.1T patent/ES2578605T3/es active Active
- 2012-10-25 WO PCT/CN2012/001432 patent/WO2013060098A1/fr active Application Filing
- 2012-10-25 US US14/354,302 patent/US9150522B2/en not_active Expired - Fee Related
- 2012-10-25 KR KR1020147013793A patent/KR101942439B1/ko active IP Right Grant
- 2012-10-25 EP EP12843502.1A patent/EP2772486B1/fr active Active
- 2012-10-25 PT PT128435021T patent/PT2772486T/pt unknown
-
2015
- 2015-02-28 HK HK15102027.6A patent/HK1201524A1/zh not_active IP Right Cessation
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO2013060098A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN103073508A (zh) | 2013-05-01 |
US9150522B2 (en) | 2015-10-06 |
CN103073508B (zh) | 2016-06-01 |
WO2013060098A1 (fr) | 2013-05-02 |
HK1201524A1 (zh) | 2015-09-04 |
JP2014532630A (ja) | 2014-12-08 |
AU2012327780A1 (en) | 2014-05-22 |
PT2772486T (pt) | 2016-07-07 |
CA2853440A1 (fr) | 2013-05-02 |
CA2853440C (fr) | 2019-10-01 |
EP2772486A1 (fr) | 2014-09-03 |
US20140256759A1 (en) | 2014-09-11 |
JP5909558B2 (ja) | 2016-04-26 |
KR20140138588A (ko) | 2014-12-04 |
ES2578605T3 (es) | 2016-07-28 |
KR101942439B1 (ko) | 2019-01-25 |
AU2012327780B2 (en) | 2016-10-27 |
EP2772486B1 (fr) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2200017I1 (hu) | Dihidronaftiridinek és rokon vegyületek, amelyek hasznosak kináz inhibitorokként proliferatív betegségek kezelésére | |
HK1201524A1 (zh) | 激酶抑制劑及治療相關疾病的方法 | |
HK1200449A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1 | |
EP2675458A4 (fr) | Composés et méthodes pour le traitement de l'hypertension | |
IL232128B (en) | Tor kinase inhibitors for cancer treatment | |
EP2773754A4 (fr) | Méthode de traitement | |
GB201110095D0 (en) | Method of treatment | |
EP2766352A4 (fr) | Composés indazole utilisés comme inhibiteurs de kinase et méthode de traitement du cancer avec lesdits composés | |
EP2590982A4 (fr) | Inhibiteur de protéine kinases et méthodes de traitement | |
ZA201306188B (en) | Mst1 kinase inhibitors and methods of their use | |
EP2691391A4 (fr) | Composés et méthodes de traitement de maladies liées à l'isocitrate déshydrogénase | |
EP2771030A4 (fr) | Compositions et méthodes de traitement de protéinopathies | |
EP2627331A4 (fr) | Méthodes de traitement de l'hyperuricemie et de maladies liées | |
HK1199261A1 (en) | Methods for treatment of diseases | |
IL231234A (en) | Aromatase inhibitor for the treatment of hypogonadism and related diseases | |
EP2788012A4 (fr) | Compositions et méthodes de traitement de maladies rénales | |
HK1216504A1 (zh) | 疾病的治療方法 | |
IL229705A0 (en) | Methods for the treatment or prevention of neurological diseases | |
EP2729155A4 (fr) | Méthodes de traitement ou de prévention d'une maladie rhumatismale | |
IL238165A0 (en) | Methods for the detection of compounds for the treatment of depression and other related diseases | |
EP2791324A4 (fr) | Procédé de traitement | |
GB201111530D0 (en) | Method of treatment | |
GB201109509D0 (en) | Method of treatment | |
GB201109266D0 (en) | Method of treatment | |
GB201103044D0 (en) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140523 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20150206 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 413/12 20060101ALI20150202BHEP Ipc: A61K 31/506 20060101ALI20150202BHEP Ipc: A61P 37/00 20060101ALI20150202BHEP Ipc: C07D 407/12 20060101ALI20150202BHEP Ipc: A61P 35/00 20060101ALI20150202BHEP Ipc: A61P 29/00 20060101ALI20150202BHEP Ipc: A61K 31/505 20060101ALI20150202BHEP Ipc: C07D 239/48 20060101AFI20150202BHEP Ipc: A61P 7/02 20060101ALI20150202BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61P 35/00 20060101ALI20150721BHEP Ipc: C07D 407/12 20060101ALI20150721BHEP Ipc: A61K 31/506 20060101ALI20150721BHEP Ipc: C07D 413/12 20060101ALI20150721BHEP Ipc: A61P 37/00 20060101ALI20150721BHEP Ipc: A61P 29/00 20060101ALI20150721BHEP Ipc: A61P 7/02 20060101ALI20150721BHEP Ipc: C07D 405/12 20060101ALI20150721BHEP Ipc: A61K 31/505 20060101ALI20150721BHEP Ipc: C07D 239/48 20060101AFI20150721BHEP |
|
INTG | Intention to grant announced |
Effective date: 20150806 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1201524 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BEIJING RECIPROCAPHARMACEUTICALS CO., LTD. Owner name: PEKING UNIVERSITY SHENZHEN GRADUATE SCHOOL |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 781093 Country of ref document: AT Kind code of ref document: T Effective date: 20160415 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012015813 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Ref document number: 2772486 Country of ref document: PT Date of ref document: 20160707 Kind code of ref document: T Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20160616 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: E. BLUM AND CO. AG PATENT- UND MARKENANWAELTE , CH |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2578605 Country of ref document: ES Kind code of ref document: T3 Effective date: 20160728 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160617 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160616 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 781093 Country of ref document: AT Kind code of ref document: T Effective date: 20160316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 5 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160716 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012015813 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1201524 Country of ref document: HK |
|
26N | No opposition filed |
Effective date: 20161219 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160616 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161025 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20121025 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161031 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160316 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20210929 Year of fee payment: 10 Ref country code: IE Payment date: 20210923 Year of fee payment: 10 Ref country code: FR Payment date: 20210930 Year of fee payment: 10 Ref country code: CH Payment date: 20210928 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20210914 Year of fee payment: 10 Ref country code: BE Payment date: 20210928 Year of fee payment: 10 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20211022 Year of fee payment: 10 Ref country code: PT Payment date: 20211025 Year of fee payment: 10 Ref country code: ES Payment date: 20211108 Year of fee payment: 10 Ref country code: DE Payment date: 20210914 Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012015813 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20221031 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20221025 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230426 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221031 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221031 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230503 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221025 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221025 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221025 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20231201 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221026 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20221026 |